Cover Image


Stivarga (Colorectal Cancer) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 321685
出版日期 內容資訊 英文 56 Pages
Back to Top
Stivarga(大腸癌症):市場預測與分析 Stivarga (Colorectal Cancer) - Forecast and Market Analysis to 2023
出版日期: 2014年11月28日 內容資訊: 英文 56 Pages





第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 預定出版的相關調查報告

第3章 疾病概要

  • 病因與病情生理
    • 病因
    • 病理生理學
  • 臨床階段
  • 症狀

第4章 疾病管理

  • 診斷及治療概要
    • 篩檢及診斷
    • 治療的指南及代表性的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要

第6章 Stivarga(Regorafenib)

  • 概要
  • 有效性
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄


Product Code: GDHC472DFR

GlobalData has released its new PharmaPoint Drug Evaluation report, "Stivarga (Colorectal Cancer) - Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Bayer/Onyx's Stivarga (regorafenib) is an orally administered multi-targeting kinase inhibitor that was approved by the FDA in September, 2012 for the treatment of metastatic CRC patients who have not, or are no longer, responding to chemotherapy and an anti-VEGF therapy or, if KRAS wild-type, Erbitux and Vectibix (FDA, press release, September 27, 2012). Stivarga was approved under FDA priority review, allowing approval within six months of submission. Approvals for Stivarga in Europe and Japan followed in 2013 (Onyx Pharmaceuticals, press release, August 30, 2013; Onyx Pharmaceuticals, press release, March 25, 2013).


  • Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Stivarga including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Stivarga for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Stivarga performance
  • Obtain sales forecast for Stivarga from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK,Japan and China)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Clinical Staging
  • 3.3. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Screening and Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Stivarga (Regorafenib)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Colorectal Cancer Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Average Body Weight and Surface Area Across the 8MM
    • 7.4.5. Individual Drug Assumptions
    • 7.4.6. Generic Erosion
  • 7.5. Primary Research - KOLs Interviewed for this Report
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Analyst
    • 7.7.2. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: TNM and Staging Classification System for CRC
  • Table 2: Symptoms of Colorectal Cancer
  • Table 3: Treatment Guidelines for CRC
  • Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013
  • Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013
  • Table 6: Leading Treatments for CRC, 2014
  • Table 7: Product Profile - Stivarga
  • Table 8: Stivarga SWOT Analysis, 2014
  • Table 9: Global Sales Forecasts ($m) for Stivarga, 2013-2023
  • Table 10: Average Body Weight and Surface Area Across the 8MM
  • Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
Back to Top